Clinical & Translational Oncology最新文献

{"title":"Health-related quality of life and lifestyle in long-term survivors of colorectal cancer and a matched non-cancer reference group.","authors":"Magdalena Esteva, Sebastià March, María Martín-Rabadan, Elena Torres-Solera, Joana Ripoll","doi":"10.1007/s12094-025-03930-0","DOIUrl":"10.1007/s12094-025-03930-0","url":null,"abstract":"<p><strong>Objective: </strong>To compare the long-term health status of a group of survivors of colorectal cancer (CRC) with a reference group of individuals who did not have cancer. We determined the physical, mental, and general health-related quality of life (HRQoL); overall morbidities and CRC-specific morbidities related to the delayed effects of treatment; and maintenance of a healthy lifestyle in these two groups.</p><p><strong>Methods: </strong>This descriptive cross-sectional study was conducted from 2016 to 2019 in the Balearic Islands (Spain). CRC patients who were diagnosed from 2011 to 2012 and survived at least 5 years were randomly selected from the Majorca and Eivissa-Formentera cancer registries. The reference group consisted of individuals matched for gender and age who had no history of cancer.</p><p><strong>Results: </strong>We examined 201 CRC survivors and 199 matched individuals without cancer. The global analysis showed that the two groups had similar scores in the physical and mental components of the Short Form 12 (SF-12) HRQoL scale and in general health status. The CRC survivors had significantly higher prevalence of general comorbidity and CRC-specific comorbidity. Multivariate analyses and calculation of odds ratios (ORs) showed that the groups had similar physical HRQoL (Model 1, OR: 1.01, 95% CI: 0.99-1.03), mental HRQoL (Model 2, OR: 0.99, 95% CI: 0.66-1.01), and general HRQoL (Model 3, OR: 1.67, 95% CI: 0.39-1.13). However, the long-term CRC survivors had significantly greater ORs for an increased overall comorbidity index, number of CRC-specific comorbidity, and obesity in all three models (P < 0.05).</p><p><strong>Conclusions: </strong>The CRC survivors and individuals without cancer had similar HRQoL, suggesting that CRC survivors do not need additional services that aim to improve HRQoL. Nonetheless, health care providers should be pro-active when caring for CRC survivors, because they are more likely to present with certain comorbidity and less likely to follow a healthy lifestyle.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3993-4002"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12460565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statins and prognosis of female breast cancer: a meta-analysis.","authors":"Francisco Cezar Aquino de Moraes, Pedro Henrique de Souza Wagner, Isabella Christina Amaral de Lara, Barbara Lins Silva, Ana Laura Soares Silva, Artur de Oliveira Macena Lôbo, Luana Izabela Azevedo de Carvalho, Michele Kreuz, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano","doi":"10.1007/s12094-025-03935-9","DOIUrl":"10.1007/s12094-025-03935-9","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) incidence is estimated to achieve over 3-million new cases and one million deaths by 2040. Beyond its physical toll, breast cancer detrimentally affects quality of life, imposing emotional, social, and financial burdens on patients and their families. Statins, commonly prescribed for managing cardiovascular health, have garnered attention for their potential role in breast cancer management. Emerging evidence suggests that statins possess anti-proliferative properties, which could impact BC progression. Understanding the potential benefits of statin therapy in BC patients is crucial for optimizing treatment strategies and improving outcomes.</p><p><strong>Methods: </strong>Hazard ratio (HR) with 95% confidence intervals (CIs) were calculated to evaluate the outcomes. The DerSimonian and Laird random-effects model was used for all pooled analyses. Heterogeneity was assessed using the I² statistic with corresponding 95% CIs, considering I² > 25% as indicative of substantial heterogeneity. Statistical analyses were conducted in R (version 4.3.2) using the \"meta\" package, with a significance level set at P < 0.05.</p><p><strong>Results: </strong>A total of 31 studies and 344,936 patients were included, of whom 72,784 (21.1%) was in the statins group and 272,152 (78.9%) was in the non-statin users group. Statin therapy was associated with a significantly reduced risks of all-cause mortality (HR 0.8583; 95% CI 0.7980-0.9231; P < 0.001; I² = 81.1%), of BCSM (HR 0.8183; 95% CI 0.7334-0.9132; P < 0.001; I² = 84.4%), and of BC recurrence (HR 0.7911; 95% CI 0.6882-0.9095; P < 0.001; I² = 48.6%). However, the analysis of DFS did not show a statistically significant difference between the groups (HR 0.8415; 95% CI 0.4220-1.6780; P = 0.624; I² = 74.2%).</p><p><strong>Conclusion: </strong>Our meta-analysis suggests that statin therapy may confer beneficial effects on clinical outcomes in female breast cancer patients, including reduced all-cause mortality, breast cancer-specific mortality, and recurrence. However, further research is warranted to confirm these findings and elucidate the mechanisms underlying these associations.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3886-3901"},"PeriodicalIF":2.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer metabolism: bridging tumorigenesis mechanisms to treatment susceptibility.","authors":"Ji'an Liu, Dan Shan, Zhaokai Zhou, Xutao Wen, Rao Fu, Bo Xu, Peng Luo, Zhengrui Li, Ling Zhang","doi":"10.1007/s12094-025-04052-3","DOIUrl":"https://doi.org/10.1007/s12094-025-04052-3","url":null,"abstract":"<p><p>Cellular metabolism has emerged as a pivotal factor influencing the viability and functionality of cancer cells. To satisfy their substantial anabolic requirements, tumor cells adopt a distinct metabolic reprogramming divergent from that of non-transformed somatic cells. This review aims to examine metabolic reprogramming in head and neck squamous cell carcinoma (HNSCC), examining its role as a fundamental aspect of cancer progression and resistance to treatment. The article systematically summarizes the key mechanisms of metabolic reprogramming in HNSCC, including enhanced glycolysis, remodeling of amino acid metabolism, and dysregulation of lipid synthesis, and discusses how these metabolic pathways facilitate tumor proliferation and metastasis by influencing the microenvironment, antioxidant defenses, and resistance to ferroptosis. Additionally, the review examines the dynamic interactions between metabolic reprogramming and the tumor microenvironment, particularly focusing on HIF-1α-driven metabolic adaptation and immune evasion mechanisms under hypoxic conditions. Finally, the potential of metabolic-targeted therapies is discussed, highlighting future research directions and their applications in personalized treatment strategies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of accelerated partial breast irradiation with multicatheter interstitial brachytherapy versus whole breast irradiation: an 11-Year clinical practice follow-up study.","authors":"Sara Garduño-Sánchez, María Isabel Villanego-Beltrán, Juan Gómez-Salgado, Javier Jaén-Olasolo","doi":"10.1007/s12094-025-04060-3","DOIUrl":"https://doi.org/10.1007/s12094-025-04060-3","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the long-term outcomes of accelerated partial breast irradiation (APBI) using multicatheter interstitial brachytherapy versus whole breast irradiation (WBI), in terms of late toxicity, cosmetic results, quality of life, and survival, in a real-world clinical setting.</p><p><strong>Methods: </strong>Updated analysis of two prospectively collected cohorts comprising 76 patients with stage I-II breast cancer treated with breast-conserving surgery followed by adjuvant radiotherapy. Patients who underwent APBI met the GEC-ESTRO eligibility criteria. We assessed follow-up and additional analyses of late toxicity, quality of life (assessed using the validated QLQ-BR23 and S-BIS questionnaires), cosmetic outcomes (via Visual Analog Scale), overall survival (OS), and disease-free survival (DFS), providing a more comprehensive evaluation of long-term outcomes.</p><p><strong>Results: </strong>At a median follow-up of 11 years, patient-reported quality of life remained significantly better in the APBI group, particularly in both physical and psychological domains, consistent with previous findings. No significant differences were observed in late clinical toxicity or cosmetic outcomes between groups. However, late mammographic findings showed a higher incidence of architectural distortion and tissue retraction in the APBI group, confirming earlier observations. The estimated 5- and 10-year OS rates were 94.7 and 81.1%, respectively. Corresponding DFS rates were 92.1% and 79.7%, with no statistically significant differences between treatment groups.</p><p><strong>Conclusion: </strong>With extended follow-up, our results reinforce that APBI using multicatheter interstitial brachytherapy is a safe and effective alternative to WBI in selected patients, providing long-term tumor control and survival comparable to WBI, while offering improved quality of life.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy sensitivity of primary glioblastoma cells and immunohistochemical markers to predict of survival of patients with of glioblastoma.","authors":"Alexandr Chernov, Aleksei Chutko, Diana Alaverdian, Vadim Kashuro, Elvira Galimova","doi":"10.1007/s12094-025-04056-z","DOIUrl":"https://doi.org/10.1007/s12094-025-04056-z","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the IDH1, p53 protein (TP53), epidermal growth factor receptor (EGFR), Ki-67 nuclear antigen, ATP-dependent helicase (ATRX), glial fibrillary acid protein (GFAP), methylated DNA-protein cysteine methyltransferase (MGMT), podoplanin (PDPN), transferrin (TR) in glioblastoma multiforme (GBM) samples. In addition, we investigated whether the expression of protein markers and the response to chemotherapy in vitro are associated with lifespan in patients with GBM.</p><p><strong>Methods: </strong>Thirty patients diagnosed with GBM were immunohistochemically (IHC) evaluated for IDH1, TP53, EGFR, Ki-67, GFAP, MGMT, ATRX, PDPN, and TR. The sensitivities of primary GBM cells to chemotherapy temozolomide (TMZ), doxorubicin (DOX), carboplatin (CARB), cisplatin (CIS), and etoposide (ETO) were analyzed by measuring cell viability with the MTT assay. Kaplan-Meier survival analysis was performed using GraphPad Prism software.</p><p><strong>Results: </strong>In this study, we found significant associations between DOX (500 μM, p = 0.0446), CARB (3000 μM, p = 0.0015) and CIS (1800 μM, p = 0.0293) with increased lifespan of GBM patients. An association between a combination of Ki-67 expression (>20%) and CARB (3000 μM, p = 0.016) with prolonged lifespan of GBM patients was shown. A relationship between Ki-67, ETO (12 μM, p = 0.0032), and an increase lifespan (13.5 vs. 6 months) in GBM patients was detected. A combination of ATRX (<60%) and CIS correlated with an increased lifespan for GBM patients (12.5 vs. 4 months, respectively, p < 0.05). Combinations of DOX (500 μM) and GFAP (<60%) were associated with prolonged lifespan for patients (p = 0.047).</p><p><strong>Conclusions: </strong>The results of the current study suggest that the expressions of IHC markers in combination with the response to chemotherapy for GBM cells may be a good predictor of lifespan patient. Hence, GBM can be grouped into prognostically relevant subgroups using these IHC markers expression signatures individually, as well as the combined with chemotherapy. In vivo drug testing on primary GBM cells in combination with expression of marker proteins can predict tumor response to personalized therapy and lifespan of the patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEOM-GEICO clinical guidelines on endometrial cancer (2025).","authors":"Sara Pérez Ramírez, Alejandro Pérez Fidalgo, María Pilar Barretina Ginesta, Ana De Juan Ferré, Lorena Fariñas Madrid, Alejandro Gallego Martínez, Fernando Gálvez Montosa, Ainhoa Madariaga, Teresa Martin Gómez, Marta Gil-Martin","doi":"10.1007/s12094-025-04046-1","DOIUrl":"https://doi.org/10.1007/s12094-025-04046-1","url":null,"abstract":"<p><p>Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Although most cases are diagnosed at an early stage, prognosis in case of relapse or metastasis remains poor. Molecular characterization of EC is highly recommended as it allows more accurate risk stratification and may modify treatment recommendations. The updated FIGO 2023 staging of EC highlights the importance of traditional clinicopathological factors, while underlining the need for molecular classification to predict outcomes. In early-stage EC, standard treatment consists of total hysterectomy and bilateral salpingo-oophorectomy. Lymph node evaluation remains controversial, as the benefits of systematic lymphadenectomy are unclear. Adjuvant treatment, consisting of radiotherapy, brachytherapy, and chemotherapy, should be chosen according to risk category. In women with advanced or recurrent EC, the combination of carboplatin and paclitaxel has long been standard treatment. However, therapeutic options have changed recently due to advances in immunotherapy. The aim of this guideline is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biochemical landscape of breast cancer: integrating serum markers with clinical prognosis and staging.","authors":"Naif Abdullah R Almalki, Mohammed Obaid Alharbi, Mirza Rafi Baig, Salma Naqvi, Fahad A Al-Abbasi, Mohammed Usaid, Firoz Anwar","doi":"10.1007/s12094-025-04023-8","DOIUrl":"https://doi.org/10.1007/s12094-025-04023-8","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a major global health concern due to its heterogeneous nature influenced by genetic, biological, and environmental factors. Serum biomarkers offer promises for improving diagnostic precision and monitoring treatment response.</p><p><strong>Objective: </strong>To evaluate the diagnostic and prognostic significance of serum biomarkers including CA-125, CA-19-9, and CA-15-3 in breast cancer patients and to explore associations with clinical and biochemical parameters.</p><p><strong>Methods: </strong>A retrospective, single-center study was conducted in the Hail region, involving 187 breast cancer patients. Data were extracted from electronic health records. Statistical analyses, including ANOVA and regression models, assessed the relationships between serum biomarkers and clinical variables, such as age, cancer stage, obesity, and laboratory parameters. Serum biomarkers CA-125, CA-19-9, and CA-15-3 were quantified using electro-chemi-luminescence immunoassay (ECLIA) assay with Elecsys kits Roche Diagnostics, with detection limits of ~ 1.0 U/ml and inter-assay variability < 7%.</p><p><strong>Results: </strong>The highest incidence was observed in women aged 46-55 (26.7%) with obesity present in 50% of cases. Advanced stages (2 and 3) comprised 82.6% of diagnoses. CA-125 levels were elevated in middle-aged patients, while CA-19-9 was higher in younger individuals. CA-15-3 showed increased levels in early-stage cancer, suggesting its utility for early detection. Obesity was linked to increased CA-125 and decreased CA-19-9 levels. Laboratory findings revealed hypocalcemia, elevated bilirubin, high GGT, and increased HbA1c, indicating potential risks of bone metastases, hepatic dysfunction, and poor glycemic control.</p><p><strong>Conclusion: </strong>Serum biomarkers demonstrate significant diagnostic and prognostic potential in breast cancer management. Findings support the importance of early detection, obesity management, and integrated monitoring to enhance outcomes and reduce relapse risk.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the role of specificity protein 1 in gliomas: pathophysiology and clinical implications.","authors":"Aida Naseri, Sepideh Razi, Nima Rezaei","doi":"10.1007/s12094-025-04058-x","DOIUrl":"https://doi.org/10.1007/s12094-025-04058-x","url":null,"abstract":"<p><p>Gliomas present a significant challenge to modern medicine as some of the most diverse and malignant brain tumors. Despite considerable developments in curative measures, the prognosis remains unsatisfactory. A prime reason is that much is obscured about the genetic regulation of glioma pathogenesis. In recent years, specificity protein 1 (Sp1) has been recognized as a central transcription factor that promotes gliomagenesis. Sp1, which is overexpressed in glioma tissues, modulates gene transcription by targeting GC boxes through its zinc finger motifs. As a result, it can influence tumor formation, proliferation, invasion, and distant migration. The present review summarizes the structure, function, and regulation of Sp1. Furthermore, this study elucidates the underlying mechanism by which Sp1 interacts with signaling pathways to fuel tumor growth and chemoresistance. Finally, the current state of Sp1's clinical implications is outlined. These findings reveal the potential benefits of Sp1 as a therapeutic target and diagnostic tool, laying the foundation for future studies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Transcriptome analysis of key genes and pathways associated with cisplatin resistance in oral squamous cell carcinoma Cal27 cells.","authors":"Yu Wang, Qiwei Zhao, Long Ding, Xiayang Liu, Zhuang Li, Xinyue Zhou, Danru Wang, Mengtian Du, Guohua Yang, Mingzhu Yin, Xiaohong Guo","doi":"10.1007/s12094-025-03998-8","DOIUrl":"10.1007/s12094-025-03998-8","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEOM-SOGUG clinical guideline for urothelial cancer (2025).","authors":"Javier Puente, Alejo Rodríguez-Vida, Elena Sevillano, Sergio Vázquez Estévez, Carlos Álvarez Fernández, Isabel Chirivella, Miguel Ángel Climent, Ovidio Fernández, Alfonso Gómez de Liaño, Begoña P Valderrama","doi":"10.1007/s12094-025-04045-2","DOIUrl":"https://doi.org/10.1007/s12094-025-04045-2","url":null,"abstract":"<p><p>This clinical guideline provides evidence-based recommendations for the diagnosis, staging, and management of bladder cancer across all disease stages. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of urothelial cancer.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}